We recently demonstrated that a panel of nine bladder cancer cell lines exhibits relative differences in their RAD001 sensitivity and accordingly, RAD001 treatment resulted in relative differences in mTOR inhibition and growth arrest, as monitored by MTT assays. The gene discussed is MTOR; the disease is urinary bladder carcinoma.